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Abstract
Cigarette smoking is one of the major risk factors for the development of chronic obstructive pulmonary disease
(COPD). Evidence is accumulating that Receptor for Advanced Glycation-End products (RAGE)-signaling is a key
pathway in the pathophysiology of COPD. To date, it is unknown how smoking affects RAGE expression. In the
current study, we investigated the effect of smoking on AGER, the gene encoding RAGE, expression and on
alternative splicing of AGER. To this end, we conducted RNA-Seq on bronchial biopsies for asymptomatic smokers
(n = 36) and never smokers (n = 40). Total AGER gene expression was accessed using DESeq2, while alternative
splicing was investigated by measuring the number of specific split reads spanning exon-exon junctions and the
total split reads. One of the major isoforms of RAGE is endogenous soluble (es) RAGE, an anti-inflammatory decoy
receptor, making up for approximately 10% of the total amount of soluble (s)RAGE. We found that smokers show
decreased total gene expression of AGER in bronchial biopsies, while the relative abundance of the esRAGE isoform
is increased. Furthermore, no difference in the serum levels of total sRAGE were observed between smokers and
non-smokers. Our data indicates that smoking initiates a protective anti-inflammatory mechanism with decreased
expression of the pro-inflammatory gene AGER and increased relative abundance of the anti-inflammatory isoform
esRAGE.
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To the editor
To date, cigarette smoking is one of the biggest public
health threats worldwide, being causative for the dead of
approximately 7 million people every year, according to the
World Health Organization (WHO). Smoking can lead to
multiple diseases, including cardiovascular diseases, lung
cancer and chronic obstructive pulmonary disease (COPD).
The underlying mechanisms of these diseases are still
largely unknown. However, there seems to be one molecu-
lar pathway which connects the three diseases, the receptor
for advanced glycation end-products (RAGE) signaling
pathway. RAGE is a pro-inflammatory pattern recognition
receptor, which is mainly expressed by type I alveolar cells.
The freely circulating soluble form of RAGE (sRAGE),
inhibits RAGE signaling by binding RAGE ligands and pre-
venting homo-dimerization of RAGE, necessary for activa-
tion. sRAGE can be formed by proteolytic cleavage or by
alternative splicing. In the latter case the transmembrane
domain, encoded by exon 10 of the gene encoding RAGE,
AGER, is spliced out, resulting in the endogenous soluble
form of RAGE (esRAGE), which passes the cell membrane
and is released into the extracellular space upon
translation.
In cardiovascular diseases it has been shown that
RAGE signaling triggers and maintains the inflammatory
state, and sRAGE can be used as a biomarker for the
development of cardiovascular diseases [1], while in lung
cancer RAGE expression may be beneficial, acting as a
tumor-suppressor [2], However, the role of RAGE
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signaling is best characterized in COPD. The gene
encoding RAGE, has been shown to be a susceptibility
gene for COPD [3]. Furthermore, sRAGE levels are de-
creased in COPD patients [4], while the levels of several
RAGE ligands are increased both locally and systemically
[5], indicating increased RAGE signaling. However, the
effect of smoking on RAGE signaling is less well studied.
It was shown that stimulation of gingival carcinoma epi-
thelial cells with cigarette smoke extract (CSE) increases
RAGE expression and the subsequent inflammatory
reaction and induces oral squamous cell carcinoma cell
invasion [6]. Furthermore, it was shown that RAGE
knock-out mice had reduced cigarette smoke-induced
neutrophilic airway inflammation [7]. However, there is
less consensus about the effect of smoking on the circu-
lating sRAGE levels, with some studies reporting no
significant differences in serum sRAGE levels between
smokers and never smokers [8], while other studies
show a decreased level of sRAGE in serum of smokers
[9]. One study even showed an increase in the serum
sRAGE levels of smokers compared to never smokers
[10]. In the current study we investigated the gene
expression levels of AGER in lung tissue of smokers and
never smokers and subsequently evaluated the level of
alternative splicing in these individuals. Alternative spli-
cing was measured using a novel, in house developed
technique, based on comparing the number of specific
split reads spanning exon-exon junctions to the total
split reads per gene.
Here, we used bronchial biopsies from 37 active
smokers and 40 never smokers without airway obstruc-
tion, which were matched based on age, sex, body mass
index and lung function (ClinicalTrials.gov Identifier:
NCT00848406) [11]. Clinical variables are shown in
Fig. 1a. All study protocols were approved by the med-
ical ethic committee of the University Medical Center
Groningen (UMCG), Groningen, The Netherlands and
all subjects provided written informed consent. Further-
more, all clinical procedures were performed according
to the standards set by the latest Declaration of Helsinki.
Bronchial biopsies were taken from segmental divisions
of the main bronchi. Total RNA was extracted from the
biopsies, converted to cDNA and the obtained cDNA
fragment libraries were loaded in pools of multiple sam-
ples in an Illumina HiSeq2500 sequencer using default
parameters for paired-end sequencing (2 × 100 bp).
Quality control (QC) metrics were calculated for the raw
sequencing data, using the FastQC tool (version 0.11.3).
The trimmed FASTQ files were aligned to human refer-
ence genome GRCh37 using HISAT (version 0.1.5)
allowing for 2 mismatches. Before gene quantification
SAMtools (version 1.2) was used to sort the aligned
reads. The gene level quantification was performed by
HTSeq (version 0.6.1p1) using Ensembl version 75 as
gene annotation database. Gene expression analysis was
conducted using raw counts of AGER and analyzed
using the R-package DESeq2. Feature counts were set as
the dependent variable, smoking status was investigated
correcting for age and gender. The splice site usage was
quantified by counting split reads mapping across
exon-exon junctions using a custom perl script (available
upon request). We processed BAM alignment files and
skipped reads marked as PCR duplicates. For each intron
in the alignment (flag N in CIGAR alignment string) we
recorded the chromosome and first and last intron base.
Afterwards, we quantified the number of reads for all
observed intron positions across alignment files from all
samples.
Here, we showed a significant decrease of total
AGER expression in smokers compared to never
smokers (Fig. 1b, smokers 1.92 ± 0.03 fpkm, never
smokers 2.48 ± 0.02 fpkm, Mann Whitney-U test, p =
0.006). To investigate whether smoking affects the ex-
pression of endogenous soluble RAGE (esRAGE), all
splicing events within the AGER gene were measured.
We were able to detect all annotated intron splicing
sites, an extension of exon 4 and the splicing of exon
10 which leads to the production of esRAGE (Fig.
1c). For all normal intron splicing sites and the alter-
native splice variant leading to an extension of exon
4, we did not observe any differences between
smokers and never smokers (Fig. 1d). Interestingly,
the splicing of exon 10 leading to the production of
esRAGE was found to be increased within smokers
(Fig. 1d-e, smokers 3.55 ± 0.12%, never smokers 2.44 ±
0.09%, Mann Whitney-U test, P = 0.03). Thus, the
total expression of AGER is decreased in bronchial
tissue of smokers, whereas the fraction of RAGE
which leads to esRAGE is increased.
While studies on the effect of smoking on RAGE
expression are limited, in vitro and murine studies
have shown that exposure of lung epithelial cells to
cigarette smoke extract or mice to cigarette smoke
increased the expression of RAGE [12]. Moreover, in
a study investigating the RAGE expression in never
smokers and active smokers using immunohisto-
chemistry, an increase in RAGE expression was
shown in mucosal cells specifically [12]. Previously,
up to 19 different alternative splice variants of AGER
were detected on mRNA level in in vitro cultured
human cells [12]. In the current study, we employed
a novel technique to detect alternative splice variants
of AGER in human bronchial biopsies. Here, we
were able to detect two alternative splice variants of
RAGE, an elongation of the fourth exon and the
splicing out of exon 10. Our study is the first to
show differences in alternative splicing of AGER in
smokers and never smokers. Here, it was shown that
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the expression of the pro-inflammatory RAGE recep-
tor decreases and the relative portion of AGER ex-
pression which leads to the production of the
anti-inflammatory decoy receptor esRAGE, increases.
This suggests an anti-inflammatory mechanism to
protect against an exaggerated immune reaction
upon smoke exposure. Dysregulation of these
anti-inflammatory mechanisms may trigger
smoke-related diseases, including cardiovascular dis-
eases, lung cancer and COPD. However, in the
current population we also found that CD8+ T-cells
were increased in current smokers compared to
never-smokers (data not shown), as low levels of
AGER expression have been observed in CD8+
T-cells before, we cannot exclude the possibility of
enhanced splicing of the transcript that leads to
esRAGE in CD8+ T-cells, influencing our results.
In summary, this is the first study investigating the ex-
pression of all splice sites within the AGER gene in rela-
tion to the total AGER gene expression. Here, we showed
that although smokers have lowered total AGER expres-
sion, the portion of AGER, which leads to the production
of the anti-inflammatory esRAGE protein is increased.
Our study provides new insight in the molecular mecha-
nisms of the human body to protect against the harmful
effects of cigarette smoking. Upon dysregulation of these
processes the susceptibility for smoke-induced diseases
may increase and restoring the balance in the RAGE path-
way may be utilized as potential therapeutic target in sev-
eral smoke-related pathologies.
Fig. 1 Smokers show lower AGER expression and increased esRAGE expression. a Patient characteristics of 37 active smokers and 40 never
smokers used for all experiments in this study. BMI = body mass index as kg/m2, Packyears = number of years smoking one pack of 20 cigarettes
per day, FVC = Forced vital capacity, FEV1 = Forced expiratory volume in one second. Data is shown as mean ± SEM. b AGER mRNA expression
was measured in lung tissue obtained from bronchial biopsy material in smokers and never smokers without airway obstruction. Gene expression
expressed as Fragments Per Kilobase Million (fpmk). c Graphical representation of the AGER exon structure and sequences spanning the exon-
exon junctions (split reads). d Percentage of expression of split reads compared to total split read count per patient for all exon-exon junctions
and alternative splicing sites. e Percentage of expression of split reads compared to total split read count per patient for esRAGE. All data is
shown as individual measurements and mean ± SEM. Significance was tested using a Mann Whitney-U test,* p ≤ 0.05, ** p < 0.01
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